GHK-Cu is a naturally occurring copper tripeptide whose plasma levels fall with age. Several small randomized and controlled trials support topical use for skin aging, and the first dedicated wound-healing RCT began recruiting in 2026. Hair, lung and systemic longevity claims rest on animal studies or confounded human data; no human trial has tested injected GHK-Cu.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Has GHK-Cu been tested in humans?
Yes, mainly for skin. Small randomized and controlled trials show topical GHK-Cu reduces wrinkle volume and increases skin density, and a Phase 2 wound-gel trial (NCT07437586) began recruiting in February 2026. No human trial has tested injected or systemic use.1
Does GHK-Cu work for hair growth?
The human data is weak and confounded. Positive studies combine copper peptides with minoxidil, dutasteride, finasteride or laser, so the copper contribution cannot be isolated, and no head-to-head trial against standard hair drugs exists.11121314
Is GHK-Cu safe?
Topical use has an excellent safety record across decades of cosmetic use, with no serious adverse events in published trials. Injectable safety is uncharacterized; the body lists active malignancy and pregnancy as contraindications.144
Is GHK-Cu legal in the US?
Topical GHK-Cu is a permitted cosmetic ingredient sold over the counter. Injectable GHK-Cu was placed in FDA Category 2 under the 2026 peptide reclassification, blocking standard compounding pending a February 2027 review.122
What would change this rating?
Results from NCT07437586, the Phase 2 topical wound trial, and any randomized trial of injectable GHK-Cu for systemic endpoints are the missing pieces named in the body.1
Aliases: Copper peptide, Gly-His-Lys-Cu, Glycyl-L-Histidyl-L-Lysine-copper(II), Copper Tripeptide-1 Sequence: Gly-His-Lys (tripeptide chelated with copper II) Molecular Weight: 424.1 Da (GHK-Cu complex) Origin: Endogenous human peptide; first isolated from human plasma by Loren Pickart in 1973
02Overview
GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper(II). It was first identified by Dr. Loren Pickart in 1973 when he found that it caused older human liver tissue to produce proteins more characteristic of younger tissue. In young adults, plasma GHK-Cu levels are approximately 200 ng/mL at age 20, but decline to about 80 ng/mL by age 60 — a striking inverse correlation with aging.
The peptide influences over 4,000 human genes related to tissue remodeling, wound healing, and anti-inflammatory processes. It is one of the most well-researched cosmetic and wound-healing peptides, with clinical data spanning several decades.
Evidence Level (Sept 2026): Strong for skin and topical wound applications (multiple human clinical studies + 2026 first dedicated RCT NCT07437586). Systemic subcutaneous/oral use remains primarily preclinical. Recent 2024–2025 work has expanded into lung inflammation/fibrosis, colitis, and infected-wound hydrogels.
03Mechanism of Action
Gene Expression Modulation
- Affects expression of >4,000 human genes (broad genomic analysis by Pickart & Margolina)
- Increases expression of 59% of genes and suppresses 41% in studied gene sets
- Modulates genes involved in DNA repair, antioxidant response, wound healing
- Upregulates collagen types I and III, elastin, and glycosaminoglycans
- Activates Wnt signaling pathway in dermal papilla cells (relevant to hair follicle regeneration)
Copper Delivery System
- GHK has an extremely high affinity for copper(II) (log K = 16.4)
- Functions as a physiological copper transport/delivery molecule
- Unlike copper chloride or copper acetate, GHK-Cu is not cytotoxic and does not cause topical irritation
- Copper is essential for lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase (antioxidant)
- Peroxiredoxin 6 target (2024): Bian et al. demonstrated GHK-Cu attenuates silicosis lung inflammation/fibrosis via Prdx6 modulation — first mechanistic lung target (PMID 38879894)
Tissue Repair Mechanisms
- Stimulates collagen and glycosaminoglycan synthesis — directly increases dermal matrix production
- Keratinocyte migration — facilitates movement across wound beds
- Angiogenesis — promotes new blood vessel formation
- Anti-inflammatory — reduces TNF-α, IL-6, IL-1β
- Antioxidant — copper-dependent SOD activity; scavenges free radicals
- Anti-fibrotic — modulates MMPs/TIMPs for organized collagen remodeling
- Epidermal stem cell stimulation — promotes skin regeneration
- Mucosal repair — 2025 colitis data: GHK-Cu alleviated weight loss, reduced DAI, attenuated colonic edema, increased goblet cells
042024–2026 Evidence Update
Wound Healing — Hydrogel Era
- Chen H et al., Biomaterials Research 2025;29:0139 — Self-healing food-derived peptide hydrogel with egg-white proteins, oxidized polysaccharides, and GHK-Cu. Infected-wound model: ~95% closure by day 12 vs 65% control, primarily via neovascularization and tissue regeneration. Broad-spectrum antibacterial + anti-inflammatory.
- NCT07437586 (Hudson Biotech, Feb 2026) — First dedicated RCT of topical GHK-Cu gel in acute standardized skin wounds in healthy adults (first posted 2026-02-27). Compares GHK-Cu gel vs matching vehicle.
Lung Inflammation and Fibrosis
- Bian Y et al., Redox Biology 2024 Sep;75:103237 (PMID 38879894 / PMC11228880) — GHK-Cu attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Mechanism: alleviates alveolar macrophage oxidative stress → blocks pulmonary fibrosis progression. 13+ citations as of 2026.
- Park JR et al., Oncotarget 2016;7(36):58405–58417 (PMC5295439) — Original LPS-induced ALI mouse study: GHK-Cu reduced ROS, TNF-α, IL-6. Foundation for respiratory applications.
- Ma W et al., Life Sci 2019 — Bleomycin-induced pulmonary fibrosis: protective effects via anti-oxidative stress + anti-inflammation pathways.
Colitis / GI
- 2025 GHK-Cu colitis data: weight loss alleviated, disease activity index (DAI) reduced, colonic edema and shortening attenuated, goblet cell numbers increased, TNF-α/IL-6/IL-1β suppressed, mucosal repair promoted. Cross-reference: 05 - Biofilms/SIBO terrain-relevant.
Skin Pharmacology Updates
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. BioImpacts 2024;15:30071 (PMID 39963574 / PMC11830136) — "Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective." Honest assessment of topical peptide delivery challenges (stratum corneum barrier, stability, formulation).
- Rakhmetova KK et al., Bull Exp Biol Med 2024 Jan;176(3):411–416 (PMID 38345677) — Gly-His-Lys-D-Ala analog skin wound regeneration in rodent model — note that D-Ala substitution is a stability modification.
Acute Cardiotoxicity (Cross-Species)
- Hsiao D et al., Biomolecules 2020;10(9):1202 — Recombinant GHK tripeptide protected zebrafish against acute waterborne-copper cardiotoxicity — proof of cross-species copper-homeostasis role.
05Primary Uses & Applications
| Application | Evidence Level | Notes |
|---|---|---|
| Skin anti-aging (topical) | Human clinical + 2026 RCT | Reduced wrinkles, improved elasticity, density; NCT07437586 |
| Wound healing (topical) | Human clinical + 2025 hydrogel data | ~95% closure day 12 vs 65% control (Chen 2025) |
| Hair growth | Preclinical + clinical | Activates Wnt signaling; stimulates follicle growth |
| Post-procedure recovery | Clinical | Used after microneedling, laser treatments |
| Acute lung injury / ARDS | Animal (LPS, bleomycin, silicosis models) | Targets Prdx6 (2024); no human trial yet |
| Pulmonary fibrosis / silicosis | Animal + mechanism | PMID 38879894 |
| Colitis / mucosal repair | Animal (2025) | Reduces TNF-α/IL-6/IL-1β |
| Cognitive function | Preliminary | Gene expression data suggests neuroprotective effects |
| Anti-inflammatory systemic | Preclinical | COPD lung fibroblast restoration in vitro |
| Bone/joint health | Preclinical | Promotes bone formation, chondrocyte activity |
Swipe table →
06Clinical Evidence
Human Studies — Topical (Skin)
- Multiple skin studies: Improved texture, reduced fine lines/wrinkles, increased skin density, improved pigmentation
- Thigh skin study: GHK-Cu improved lines, wrinkles, density, mottled pigmentation
- NCT07437586 (Hudson Biotech, Feb 2026): First dedicated RCT — vehicle-controlled, standardized skin wounds in healthy adults
Wound Healing
- Accelerated wound closure confirmed across clinical settings
- 2025 hydrogel innovation (Chen et al., Biomaterials Research 29:0139) — infected-wound model 95% closure vs 65% control by day 12
Hair Studies
- Evidence of improved hair quality and density (Wnt signaling mechanism)
Gene Expression (Pickart & Margolina)
- 2018 review (Int J Mol Sci 19(7):1987): "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data"
- 2015 review (BioMed Res Int): "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration"
- 2024 BioImpacts critical assessment of topical delivery barriers
07Uses
⚠️ Disclaimer: Research protocols, not medical recommendations. Systemic use remains preclinical.
Topical
- Concentration: 0.2–2% in cosmetic preparations
- Applied 1–2× daily to target areas
- Most well-studied route for skin applications
- 2024 BioImpacts review: formulation matters (liposomes, nanocarriers needed for barrier penetration)
Oral
- Less well-studied but used in some protocols
- Bioavailability uncertain — peptide stability in GI tract is the open question
08Safety Profile
| Aspect | Assessment |
|---|---|
| Overall safety | Excellent — well-tolerated across clinical studies |
| Cytotoxicity | NOT cytotoxic (unlike copper chloride/acetate) |
| Contraindications | Active malignancies — promotes cell growth signals that could support cancer proliferation |
| Pregnancy/breastfeeding | Contraindicated — insufficient safety data |
| Hormone-sensitive cancers | Discuss with oncologist before use |
| Long-term systemic safety | Not characterized |
Swipe table →
09Source & Origin
- Discovered by: Dr. Loren Pickart (1973) — first described as a liver cell growth factor
- Natural occurrence: Present in human plasma, saliva, and urine
- Decline with age:
- Patent history: Originally patented by ProCyte Corporation for wound healing applications
- Family: Copper-binding peptides — see also Plasmalogens and Membrane Health for broader membrane lipid context
10Peptide Combinations
- GHK-Cu + NAD+: Synergistic — GHK-Cu targets tissue remodeling, NAD+ targets cellular energy
- GHK-Cu + BPC-157: Combined for systemic tissue repair (see Wolverine Stack - TB-500 + BPC-157 Evidence)
- GHK-Cu + Semax: Tissue repair + cognitive support (no mechanism overlap)
- Never mix different peptides in the same syringe or vial
11GHK-Cu (Copper Peptide) — Evidence Taxonomy and Clinical Claims Audit
Dossier status: Active — 2026Q3 audit update Evidence tier (revised 2026-09-25): Tier 2 for skin regeneration and wound healing (multiple controlled human trials); Tier 4–5 for hair regrowth and systemic/longevity claims
Overview
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide-copper(II) complex first isolated from human plasma in 1973.
It is positioned in clinic menus (Nava Health, Ways2Well, Javan Anti-Aging) alongside BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4) as part of the regenerative / longevity peptide stack. Unlike most gray-market peptides, GHK-Cu has a substantial in-vitro and animal dossier and a small but growing body of controlled human trials — primarily in skin regeneration and wound healing.
Molecule
| Property | Detail |
|---|---|
| Sequence | Gly-His-Lys (tripeptide) + Cu²⁺ |
| Plasma concentration (young adult) | ~200 ng/mL |
| Plasma concentration (age 60) | ~80 ng/mL |
| logD (pH 4.5 / 7.4) | −2.49 ± 0.33 / −2.49 ± 0.35 (highly hydrophilic — delivery challenge) |
| Endogenous role | Copper transport, collagen/elastin modulation, antioxidant signaling |
| Discovery | Pickart 1973 (plasma fraction with hepatocyte growth–promoting activity) |
Swipe table →
Tier 1 — In-Vitro Evidence (Robust, Reproducible)
- Collagen/elastin/GAG synthesis: GHK-Cu at 0.01–100 nM increases collagen and elastin production in human adult dermal fibroblasts (HDFa); upregulates MMP1/MMP2 (low nM) and TIMP1 at all tested concentrations, shifting the proteolysis balance toward net matrix deposition (Badenhorst et al. 2016, doi 10.4172/2329-8847.1000166).
- Decorin, biglycan, versican: Stimulated in dermal equivalents (Pickart 2018, PMC6073405).
- Keratinocyte proliferation: Topical GHK-Cu cream twice daily for 12 weeks increased dermal keratinocyte proliferation and pro-collagen synthesis (cited in Badenhorst 2016).
- Dermal–epidermal junction (DEJ): Biotinyl-GHK (BT) + ascorbyl-succinyl-GEKG peptide complex increases collagen XVII, laminin, and nidogen expression in cultured human epidermal keratinocytes and ex vivo human skin (Int J Mol Sci 2020, doi 10.3390/ijms21010073).
- Connectivity Map / gene regulation: Affects expression of ~31.2% of human genes (≥50% change threshold). Activates DNA repair, proteasome, anti-inflammatory pathways; suppresses NF-κB–driven inflammatory genes (Pickart & Margolina 2018, PMC6073405).
- Antioxidant enzymes: ↑ SOD, glutathione peroxidase in treated fibroblasts and rodent skin.
- Neurotrophic signaling: ↑ NGF, NT-3 in neuronal cultures; neuroprotective in rodent ischemia models (Pickart 2012, PMC3359723).
Tier 2 — Animal Evidence (Strong)
- Wound healing (rodent, diabetic and ischemic): ↑ wound contraction, granulation tissue, epithelialization, angiogenesis.
- Skin regeneration: ↑ dermal thickness, collagen density in photoaged mouse and rat skin.
- Hair follicle cycling (mouse, 2023): Copper-peptide microemulsion accelerated anagen entry faster than minoxidil in murine model (cited in Kuceki 2025 protocol rationale).
- Pulmonary fibrosis (rodent): Bleomycin-induced lung fibrosis attenuated by systemic GHK-Cu; reduced collagen deposition, ↓ TGF-β signaling (preclinical only — no completed human trial as of 2026-09).
- Neuroprotection: Reduced infarct volume in rodent stroke models; ↑ BDNF, ↓ microglial activation.
Tier 3 — Human Clinical Evidence
Skin Regeneration (Strongest Signal)
| Study | n | Design | Dose / Form | Duration | Result |
|---|---|---|---|---|---|
| Pickart 2018 (review of 3 prior RCTs) | 71 | Open facial-cream study | GHK-Cu 2% cream | 12 weeks | ↑ skin density/thickness, ↓ laxity, fine lines, wrinkles |
| Thigh-skin RCT (cited in Pickart 2018) | — | Comparator RCT | GHK-Cu vs vitamin C vs retinoic acid | 12 weeks | Collagen production in 70% vs 50% (vit C) vs 40% (retinoic acid) |
| Badenhorst 2016 (J Aging Sci) | 40 | Randomized double-blind split-face, nano-carrier GHK-Cu vs Matrixyl 3000® vs vehicle | NRFS serum | 8 weeks | 31.6% ↓ wrinkle volume vs Matrixyl 3000® (p=0.004); 55.8% ↓ vs vehicle (p<0.001); 32.8% ↓ wrinkle depth vs vehicle (p=0.012) |
| Yuvan Research / Wayne Carey 2023 (McGill, RCT) | 21 | Randomized, gel formulation | Topical GHK-Cu gel | 3 months | 28% average ↑ subdermal echogenic density (collagen/elastin proxy) on high-resolution ultrasound; top quartile: 51% ↑ (EurekAlert May 2023) |
| Peptide complex (BT + AST) 2020 RCT | 22 | Open-label, Asian women aged 40–60 | 200 ppm peptide complex, twice daily | 2 weeks | Significant improvement in 5 wrinkle sites (crow's feet, nasolabial, glabella, forehead, neck lines), all p<0.05 (Int J Mol Sci 2020) |
Swipe table →
Interpretation: Topical GHK-Cu at 0.4–2% over 8–12 weeks produces statistically and clinically meaningful improvements in facial wrinkle volume, dermal collagen density, and skin laxity. Effect sizes are consistent across independent groups (Pickart/Badenhorst/Yuvan) and exceed Matrixyl 3000® (the most widely used cosmetic GHK derivative) in head-to-head testing.
Wound Healing (Phase 2 Active)
- NCT07437586 (recruiting since Feb 2026): Topical GHK-Cu gel for acute skin wound re-epithelialization, Phase 2, primary endpoint time-to-complete-closure. Will be the first industry-sponsored GHK-Cu wound RCT with GCP-grade endpoints.
Hair Regrowth (Weak — Mechanistic Plausibility, Insufficient Human Proof)
The honest evidence shape (as of 2026-09):
| Study | n | Design | Result | Limitation |
|---|---|---|---|---|
| Pyo 2007 (Arch Pharm Res, PMID 17703734) | — | In-vitro isolated human follicles + DPC | AHK-Cu (NOT GHK-Cu) promoted elongation | Not human in-vivo |
| Uno & Kurata 1993 | — | Mouse model | PC1031 ≈ minoxidil follicular enlargement | Animal only |
| Lee/Kim 2016 (ALAVAX, Ann Dermatol) | 45 men | RCT, GHK + 5-aminolevulinic acid, daily | +71.5 hairs at 50 mg/mL (p<0.05) vs +9.6 placebo | Not pure GHK-Cu — combined with 5-ALA; ALA alone shows some activity |
| Tanaka 2018 (PMID 30057663) | 18,918 men | Retrospective, copper peptide as 1 of 14 ingredients + oral finasteride + minoxidil | Patient satisfaction only | No control; copper not isolable from 14 other variables |
| Bertin 2018 (PMID 29452017) | 4 | Case series, copper peptide 1% + fractional laser + finasteride + growth factors | Qualitative improvement | n=4, four simultaneous variables |
| Pamela 2021 (J Clin Exp Dermatol Res) | 6 | Pilot, single-blind, Cu-tripeptide + RF vs saline + RF | 26–50% improvement (Scale 1) vs 0–25% placebo | n=3 per arm; tiny pilot |
| Kuceki 2025 (JAAD Int, PMID 40225275) | 7 men | Retrospective 5-session microinfusion tattoo: 0.5% minoxidil + 0.1% dutasteride + 1.2% copper peptides | Median SALT 40.0% → 7.5% (p<0.001); median TSAR 26.5% | Three-drug cocktail — copper contribution not isolable; 3-drug superiority over 2-drug (Kuceki 2023) was significant (p=0.0025) but minoxidil+dutasteride alone already works |
Swipe table →
Synthesis: As of August 2026, ClinicalTrials.gov lists no registered trial of any copper peptide for alopecia or hair loss. The only registered GHK-Cu trial (NCT07437586) is testing a gel on punch-biopsy wounds — the serious controlled human work is being done on skin, not scalp. There is no head-to-head RCT of copper peptides vs minoxidil or finasteride as monotherapy. Any "natural minoxidil alternative" framing overstates the human evidence.
What is real: mechanism (DPC proliferation, Wnt/β-catenin activation, VEGF upregulation, possible 5α-reductase inhibition at type 1), animal follicle data, and consistent (though confounded) human signal when copper peptides are added to proven drugs.
Systemic / Longevity (No Quality Human Evidence)
- No RCTs of injectable GHK-Cu for systemic anti-aging, cognitive, or longevity endpoints.
- Endogenous plasma decline is well-documented but causation for the aging phenotype remains correlational.
- Community practice of subcutaneous GHK-Cu 1–2 mg 2–3×/week is pharmacokinetically extrapolated from animal data; no human PK study exists.
Tier 4 — Safety
- Topical: Excellent safety profile across decades of cosmetic use; no serious adverse events in any published RCT.
- Systemic / injectable: No formal human safety RCT. Theoretical concerns include copper overload (monitor ceruloplasmin, free copper with chronic dosing), zinc depletion (commonly co-supplemented), and immune reactions to chronic peptide administration.
- Drug interactions: None documented; topical GHK-Cu does not interact with systemic drugs.
- Pregnancy / pediatric: No data; cosmetic use typically avoided.
Mechanism (Consolidated)
- Copper chaperone: Delivers bioavailable Cu²⁺ to copper-dependent enzymes (lysyl oxidase, SOD, cytochrome c oxidase).
- Matrix remodeling: Shifts MMP/TIMP balance toward net deposition; ↑ collagen I/III, elastin, GAGs, decorin.
- Epigenetic regulation: Binds DNA promoter regions, modulates chromatin accessibility; affects >31% of human gene transcripts.
- Anti-inflammatory: Suppresses NF-κB; ↑ IL-10, ↓ TNF-α in skin models.
- Stem cell support: ↑ fibroblast proliferation and migration; supports DPC and follicular stem cell function.
- Antioxidant: ↑ SOD, glutathione peroxidase; ↓ lipid peroxidation.
Delivery Systems (Why It Matters)
Native GHK-Cu is highly hydrophilic (logD −2.49) — it does not penetrate skin efficiently without carriers. Most modern formulations use one of:
| Delivery system | Example products | Evidence level |
|---|---|---|
| Nano-lipid carriers | NRFS serum (Badenhorst 2016), nano-emulsions | Strong (RCT) |
| Liposomal encapsulation | Various cosmeceuticals | Moderate |
| Biotinyl conjugation (BT) | Peptide complex (Int J Mol Sci 2020) | Strong (RCT) |
| Palmitoyl conjugation (Matrixyl 3000®) | Most mass-market cosmetic serums | Moderate; less effective than native GHK-Cu in head-to-head |
| Microemulsion | Animal hair studies (2023) | Preclinical |
| Tattoo / microinfusion | Kuceki 2025 protocol | Promising for hair combination, but confounding |
| Subcutaneous injection | Community clinic practice | No PK or efficacy data |
Swipe table →
FDA / Regulatory Status
- Topical cosmetic: FDA does not regulate cosmetics for efficacy; GHK-Cu is a permitted cosmetic ingredient (INCI: Copper Tripeptide-1).
- SkinMedica / Neova / Dr. Loretta: Cosmeceutical products containing GHK-Cu sold over-the-counter.
- FDA-cleared device adjacency: SkinMedica NeoCu and similar products leverage 510(k) device clearances for dermatology use.
- Compounded injectable/topical: Off-label; 503A pharmacy compounding remains the primary US supply route.
- 2026 Reclassification: Injectable GHK-Cu classified under FDA Category 2 restricted bulk substances per the 2026 peptide reclassification framework — not eligible for 503A compounding without further review. Scheduled before the Feb 2027 PCAC meeting. Topical remains legal cosmetic.
- No FDA-approved indication for any GHK-Cu product (injectable or topical).
Commercial Landscape
- Cosmeceutical: SkinMedica (Allergan/AbbVie), Neova, Dr. Loretta, NIOD, The Ordinary ("Multi-Peptide + Copper Peptides" serum)
- Clinic compounding: 503A pharmacies (Tailor Made, Innovation, Empower — all under 2026 reclassification pressure)
- Wellness clinic chains: Nava Health, Ways2Well, Javan Anti-Aging (position as "youth peptide")
- Supplement formulations: Oral copper peptide capsules (low bioavailability; limited rationale)
- Market: Global copper peptide skincare market estimated $250–400M (2025); projected ~12% CAGR through 2030
Claims Audit Focus Areas
- Skin regeneration / anti-aging: Supported (Tier 2 human evidence)
- Wound healing: Supported for topical (Tier 2-3), pending Phase 2 NCT07437586
- Hair regrowth: Adjunctive only — no standalone human RCT
- Systemic anti-aging / longevity: Not supported by human evidence
- Safety: Strong for topical; theoretical concerns for chronic injectable
- Topical vs injectable: No comparative data; delivery challenge makes topical efficacy formulation-dependent
Competitive Positioning
| Comparator | Position vs GHK-Cu |
|---|---|
| Epitalon | Different mechanism (telomerase); GHK-Cu has stronger human skin data |
| BPC-157 (Body Protection Compound) | BPC-157 is systemic/regenerative; GHK-Cu is skin-targeted |
| TB-500 (Thymosin Beta-4) | TB-500 is systemic; GHK-Cu has stronger topical evidence |
| Retinoids | Comparable wrinkle reduction; retinoids have longer track record and irritation profile |
| Vitamin C | GHK-Cu outperformed vitamin C in thigh-skin collagen production (70% vs 50%) |
Swipe table →
Personalization Angles (Clinic Menu)
- Nava Health: Pitch co-branded evidence brief — strongest human data is on facial skin (matches their positioning)
- Ways2Well: FDA-regulated sourcing positioning — caveat that topical use remains legal cosmetic even after injectable reclassification
- Javan Anti-Aging: Pitch claims audit — replace "longevity" framing with "skin regeneration" + "wound healing" (matches evidence)
12Where to get it
GHK-Cu is sold mainly through gray-market vendors whose products are not independently tested. We don't link to sellers of compounds like this, affiliate or otherwise. How we make money
13Connections
14Sources
- ClinicalTrials.gov NCT07437586 (2026). Topical GHK-Cu Gel for Acute Skin Wound Healing (Hudson Biotech, first posted 2026-02-27)NCT07437586
- Bian Y, Deng M, Liu J, et al. (2024). The glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology 75:103237. PMID 38879894 / PMC11228880 — silicosis + Prdx6 mechanismPubMed 38879894 · PMC11228880
- Park JR, Lee H, Kim SI, Yang SR. (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget 7(36):58405–58417. PMC5295439PMC5295439
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. (2024). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts 15:30071. PMID 39963574 / PMC11830136 — critical topical delivery reviewPubMed 39963574 · PMC11830136
- Rakhmetova KK, Mishina ES, Bobyntsev II, et al. (2024). Effects of Gly-His-Lys-D-Ala Peptide on Skin Wound Regeneration Processes. Bull Exp Biol Med 176(3):411–416. PMID 38345677 — D-Ala analog wound modelPubMed 38345677
- Chen H, Yang P, Xue P, et al. (2025). Food-Derived Tripeptide–Copper Self-Healing Hydrogel for Infected Wound Healing. Biomaterials Research 29:0139. doi 10.34133/bmr.0139 — 95% closure vs 65% controlDOI 10.34133/bmr.0139
- DOI 10.4172/2329-8847.1000166DOI 10.4172/2329-8847.1000166
- PMC6073405PMC6073405
- DOI 10.3390/ijms21010073DOI 10.3390/ijms21010073
- PMC3359723PMC3359723
- PubMed 17703734PubMed 17703734
- PubMed 30057663PubMed 30057663
- PubMed 29452017PubMed 29452017
- PubMed 40225275PubMed 40225275
15Entry history
Latest content update.
Folded in 1 earlier page: ghk-cu-copper-peptide-evidence-taxonomy-and-clinical-claims-audit.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.